Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress • Advanced MYCHELANGELO™ I trial dose escalation to Cohort 5; Presentation of additional monotherapy data and planned expansion into Phase 2 settings expected in mid-2024 • Presented new preclinical data demonstrating potential of a MYC-targeting epigenomic controller in NSCLC at AACR 2024 • Company to present new preclinical data demonstrating durable epigenomic upregulation and other OMEGA platform capab ...